LASIK microkeratomes, a cost-effective solution

Article

At this year's ESCRS in Paris, Moria showcased its One range of single-use, high precision, handheld surgical instruments, including the One Use-Plus SBK.

At this year's ESCRS in Paris, Moria showcased its One range of single-use, high precision, handheld surgical instruments, including the One Use-Plus SBK. This new generation of LASIK microkeratomes reportedly achieves accuracy and visual results equivalent to femtolasers at a fraction of the cost.

The One Use-Plus system is a linear, automated, microkeratome featuring a nasal hinge and two head sizes (90 and 130) for customizable flap thickness of 100 µm and 130 µm on average, respectively. In addition to this surgeons can benefit from three single use suction rings, -1, 0 and +1, to accommodate for all keratometries. The company claims the instrument can help doctors achieve predictable, thin flaps with planar profiles, resulting in outstanding visual outcomes that are equivalent or better than those achieved with a femtolaser with less discomfort to the patient.

Moria has been working with corneal surgeons in the field of DSAEK on the relatively new technique of Ultra-Thin DSAEK.

For more information on the One range of products visit the company's website at www.moria-surgical.com

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.